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Abstract
Background: To investigate the factors related to approval after review by an Institutional Review Board (IRB), the
structure equation model was used to analyze the latent variables ‘investigators’, ‘vulnerability’ and ‘review process’
for 221 proposals submitted to our IRB.
Methods: The vulnerability factor included vulnerable cases, and studies that involved drug tests and genetic
analyses. The principal investigator (PI) factor included the license level of the PI and whether they belonged to our
institution. The review factor included administration time, total review time, and revision frequency. The revision
frequency and total review time influenced the efficiency of review.
Results: The latent variable of reviewing was the most important factor mediating the PIs and vulnerability to IRB
review approval. The local PIs moderated with genetic study and revision frequency had an impact on the review
process and mediated non-approval.
Conclusions: Better guidance of the investigators and reviewers might improve the efficiency with which IRBs
function.
Background
Institutional Review Boards (IRBs) assess research pro-
posals to ensure that they adhere to research regulations,
adequately protect the rights and welfare of study partici-
pants, and are ethically sound. Accreditation of an IRB by
the National Health Institute ensures that human safety is
not compromised during the conduct of approved medical
research. An IRB should assess the adequacy of structural,
procedural, and performance-related aspects of all studies
brought before it. Performance problems related to the ab-
sence of systematic assessment of the outcomes of this
system of oversight have not been addressed [1]. There is
no mechanism at the national level to gather systematic
evidence on the intersection between research and IRB
review [2].
Many investigators have expressed dissatisfaction with
the IRB system, characterizing it as being dysfunctional
[3], overburdened [2, 4], and over-reaching [5]. Principal
investigators (PIs) complain that the problems of the re-
view process conducted by IRBs include the inefficiency
with which it identifies irrational decisions [6] and its in-
consistency [7]. Research sponsors object that IRB re-
view is time consuming, and that the associated delays
can significantly increase the costs of research. The
current IRB system has also been described as outdated
and inappropriate for the scope and type of research be-
ing conducted in the 21st century [8]. Proposals to im-
prove the performance of IRBs include increasing the
efficiency of the review process and reducing the
amount of time devoted to administrative tasks prior to
board review [1].
The significant demands on the time and resources of
PIs that are associated with addressing the various chal-
lenges associated with IRB approval reduce the willing-
ness of PIs to participate in future research projects [9].
The greatest delay in approval is seen early in the IRB
process, with PIs requiring an average of 45.1 ± 31.8 days
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to submit their study to the IRB [10]. The U.S. National
Institutes of Health has suggested training programs for
junior PIs and research staff to educate them more about
the importance of the protection of human research sub-
jects and the IRB review process [11]. However, there are
no reports of the extent to which better appreciation by
PIs of patient rights and the IRB process affects the likeli-
hood of a positive outcome of the IRB process.
With regard to vulnerability, vulnerable groups are
commonly understood to include pregnant women, pris-
oners, children, and incompetent adults. Who is a re-
search object? [12] have highlighted the challenges
associated with trying to protect such vulnerable groups
during studies that involve new drugs. Reporting of ser-
ious adverse drug events to IRB helps to promote the
safe use of pharmaceuticals [13]. A study by [14] indi-
cated that descriptions of adverse events associated with
15 drugs and reported in clinical practice as structured
event descriptions were 2- to 10-fold more complete
than the descriptions of the same events in the FDA
safety databases. Another important issue relates to
obtaining informed consent from vulnerable groups in
studies that involve genetic research; members of these
groups can pose challenging questions related to ethical
and regulatory standards. The complexity and controver-
sial nature of many ethical issues in genome research re-
flects the limited common ground between genetic
researchers and IRB professionals [15] and differences
between these two communities in disclosing contradict-
ory research findings [16]. However, we do not know
how these variables affect vulnerable groups and the
likelihood of IRB approval.
Despite recognition of the need to evaluate the effect-
iveness of IRB review, no published study has evaluated
the effectiveness of the complicated IRB structural
model. Several studies that evaluated the structure,
process and outcome of IRB review have documented
inconsistencies and inefficiencies [7]. Reports on the
most important issues concerned with IRB approval have
focused on three areas: (1) the total time of review and
the rejection frequency; (2) the license level and institu-
tion of the PI; and (3) the use of vulnerable groups in
drug and genetic studies. Little is known about the com-
plicated relationships between PIs, IRBs, and vulnerable
groups. To investigate the factors involved in IRB review
and approval, we analyzed research reviewed by our IRB
over a 5-year period, using the structure equation model
(SEM) for assessment of the latent variables of IRB re-
view, PIs, and vulnerable groups.
Methods
Study design
In December 2012, we administered a retrospective sur-
vey of the proposals submitted for review by our IRB
between January 2008 and December 2012. The study
design met the requirements of the Helsinki Declaration
and the design was approved by the IRB of the Armed
Forces Kaohsiung General Hospital. The proposals were
decoded for the names of the PIs and reviewers. We
established whether the researchers belonged to our
organization and collected details regarding their license
level. The four license levels included medical ethics
credit from the organization for 6 h per year, >6 h per
year, credit from the Department of Health, and credit
from a collaborative institutional training initiative
(CITI) program qualification. We defined the vulnerabil-
ity of the population (vulnerable/non-vulnerable), type
of risk (drug/non-drug), and need to protect the confi-
dentiality of the information collected (genome/non-
genome). The review included: (1) administration time
required by the Secretary of the IRB to check on in-
formed consent and proposal documents; (2) total
review time for informed consent, comparison of risks
and benefits, and recruitment of the test population by
scientific and non-scientific reviewers; and (3) the fre-
quencies of revisions and resubmissions by the PIs after
the primary and secondary reviews.
Study data
We surveyed 221 proposals, including human studies,
which were submitted to our IRB over a 5-year period.
Proposals for which the application was withdrawn be-
fore completion of the review were excluded. The secre-
tary of our IRB checked the documents against the
checklist. The documents included details related to the
study method and materials, the recruitment plan, levels
of risk and benefit in the study population, inclusion of
vulnerable cases (our definition of vulnerable cases in-
cluded children, pregnant women, patients with mental
illness, prisoners, students, and patients with disability),
payment and compensation plan, informed consent, the
license held by the PIs and their assistants, whether the
PIs worked in our organization, protection of human
subjects, and privacy and data confidentiality. If the pro-
posal involved a genetic study, the PIs were required to
have a qualification in the ethics of genetic research by
Human Research Act of Taiwan. We asked for a full-
board review for drug studies, such as phase-one
through to phase-four clinical trials. The clinical trials
were assigned to full board review. If these documents
were complete, the proposal was sent to the Chair of the
IRB within 3 days. If not, it was returned to the PIs. The
revision frequency was recorded to assess the perform-
ance of the PIs.
Our IRB comprises 15 members: six non-scientific re-
viewers, nine scientific reviewers, six women, nine men, six
members who were not affiliated with our organization,
and nine members employed by our organization. All IRB
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members receive annual accreditation in research ethics
and undertake this work on a voluntary basis.
Before discussion by the IRB, one non-scientific and
one scientific reviewer were assigned by the Chair of the
IRB to review the proposal. The total review time was
limited to 2 weeks and the duration of the review was
recorded for further analysis. There were four outcomes
of the review: ‘agree’, ‘agree with revision’, ‘review again
after revision’, and ‘not recommended’. These outcomes
were forwarded to the full board for further discussion
every month. We classified the board review outcome as
approval or not; whereas ‘agree’ and ‘agree with revision’
were assigned to the approval group, the other two out-
comes were assigned to the control group.
Statistical analysis
We used the SPSS version 20 statistical software package
with the analysis of moment structure (AMOS). The
SEM was applied to test the mediating variables between
the review outcome and the observed variables. The
SEM clarified the extent of the relationships between the
variables as well as the chain of cause and effect. In
other words, SEM results did not merely show the em-
pirical relationships between the variables when defining
the practical situation. For this reason, SEM was used to
test the hypotheses. This study also used several indices
to evaluate overall model fitness, including the χ2 test of
absolute fit (p > 0.05), test of relative fit by the goodness-
of-fit index (GFI > 0.90), the adjusted goodness-of-fit index
(AGFI > 0.90), the Tucker–Lewis index (TLI > 0.95), the
comparative fit index (CFI > 0.90), and the root mean
square error of approximation (RMSEA < 0.05). The mod-
eling of latent variables was designed to consider three
categories: PIs, review process by reviewers, and the vul-
nerability of subjects or assessment of risks associated
with drug-related and genetic tests. The latent variable of
the PI factor included observed variables, such as the li-
cense level of the investigators and whether they belonged
to our institution. The latent variable of the reviewing
process included observed variables, such as administra-
tion and secretarial time, board-member review time, and
revision frequency. The latent variable of vulnerability in-
cluded observed variables, such as the involvement of vul-
nerable cases, and drug and genetic studies. The
descriptive analysis involved comparison between the ap-
proval group and control group using a cross table and
Student’s t-test.
Results
We reviewed 221 proposals submitted to our IRB over a
5-year period. Of these, 159 proposals were approved, 56
were not approved, and six were exempt from a deci-
sion. The six exempt reviews were excluded. The type of
review (expedited/full board), involvement of vulnerable
subjects, involvement of drug use, involvement of gen-
etic analysis, and the duration of PI training did not dif-
fer significantly between the group of applications that
were approved and those that failed to receive approval.
There were significantly more non-approvals for applica-
tions from PIs within our organization than for applica-
tions from PIs from outside our institution (p = 0.014).
The administration time required for checking by the
secretary of our IRB was longer in the group of applica-
tions that were not approved (p = 0.008) than in the
group that received approval. The revision frequency in
the group of applications that were not approved was
significantly higher than in the group of applications that
were approved (p < 0.001). The total review time was sig-
nificantly longer in the group of applications that were
not approved than in the group of applications that were
approved (p = 0.002) (Table 1).
The non-standardized structure equation revealed the
interactions between the latent variable of vulnerability
and PIs and review (χ2 = 25.706, degrees of freedom = 18,
p = 0.107); between the duration of drug study and the
duration of review; between the involvement of a genetic
study and the revision frequency; between the involve-
ment of a genome study and whether the PIs belonged to
our organization; and between the revision frequency and
whether the PIs belonged to our organization (Fig. 1).
When estimates covariance among exogenous vari-
ables (Fig. 2 and Table 2) revealed the significant rela-
tionship between PIs and review time (estimate = −0.031,
p = 0.04), drug study and review time (estimate = 1.515,
p = 0.014), genome study and revision frequency (esti-
mate = 0.093, p < 0.0001); genome study and whether the
PIs belonged to our organization (estimate = −0.047, p <
0.0001); and revision frequency and whether the PIs
belonged to our organization (estimate = −0.126, p = 0.04).
When estimates of regression weight, the drug study and
vulnerable case revealed no significant (estimate 1.12, p =
0.127; estimate 3.25, p = 0.117 respectively) to latent vari-
able of vulnerability in genome study set to zero. The li-
cense is significant to PI (estimate −1.90, p = 0.011) when
set the local variable to zero. The total review time and
administers time is significant to review (estimate
55.54, p < 0.001; estimate 2.01, p < 0.001 respectively)
when set revision to zero. To approval, review (estimate
0.49, p = 0.011) is significant than PI and vulnerability (es-
timate −0.44, p = 0.379; estimate −1.77, p = 0.244 respect-
ively). When estimate of variances of exogenous variables,
the e1, e2, e3, e4, e5, e6, e7, e8 and d1 (estimate 0.18, 0.08,
0.17, 0.18, 0.08, 0.42, 702.25, 0.85, 0.16; p < 0.001, <0.001,
<0.001, <0.001, =0.020, <0.001, <0.001, <0.001, <0.001
respectively).
Confirmation of the model fitness (GFI = 0.975, AGFI =
0.937, TLI = 0.933, CFI = 0.967, and RMSEA = 0.044) re-
vealed that the model was appropriate (Table 3).
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Discussion
This study revealed that revision frequency and total re-
view time influenced reviewing, and that the latent vari-
able of reviewing was the most important factor in
mediating the PIs and vulnerability to IRB review ap-
proval. And this study is the first application of the
AMOS to test the systemic pathway for the hypothesis
on the relative delay variables of the reviewing process.
AMOS revealed the reviewing process to be the medi-
ator, which is not the only role with the responsibility of
non-approval. The latent variables ‘vulnerability’ and
‘PIs’ played a significant role in approval. Many authors
have expressed dissatisfaction with the IRB system [2–6].
This is the first use of SEM to provide a more compre-
hensive assessment of the factors that influence the suc-
cess of applications brought before IRBs. The SEM
Table 1 Demographic data of the proposals reviewed within the past 5 years by our IRB
Non-approval Approval X2∕t P
n = 56 n = 159
Type
Expedited 50 (89.3 %) 125 (78.6 %) 3.113 0.109
Full-board 6 (10.7 %) 34 (21.4 %)
Vulnerable case 18 (32.1 %) 59 (37.1 %) 1.154 0.338
Drug study 8 (14.3 %) 13 (8.2 %) 1.754 0.196
Genetic study 16 (28.6 %) 38 (23.9 %) 0.481 0.480
PI training 3.996 0.262
6 h 0 1 (0.63 %)
> 6 h 2 (3.6 %) 13 (8.2 %)
DOH 50 (89.3 %) 141 (88.7 %)
CITI program 4 (7.1 %) 4 (2.5 %)
Within organization 49 (87.5 %) 108 (67.9 %) 8.565 0.014
Administration time (day) 1. 27 ± 1.51 0. 78 ± 1.03 2.676 0.008
Revision frequency 1. 82 ± 0.57 1. 40 ± 0.76 3.744 0.000
Total review time (day) 47. 8 ± 50.5 31. 4 ± 24.1 3.203 0.002
N = 221, excluded 6 exempt review
DOH credits from Department of Health, CITI collaborative institutional training initiative
Fig. 1 Conceptual construct of the structural equation models of vulnerability, PIs, and review process on the approval outcome
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found that both the IRB review process and PI factors af-
fected the likelihood of approval of a request. Most of the
literature related to the value of IRBs has focused on is-
sues related to their structure and operational processes
instead of the measurement of outcomes [1, 9, 10]. In this
study, our use of dichotomy approval and non-approval to
reflect the effectiveness and efficiency of the IRB meant
that other functions of the IRB were ignored. The func-
tions of the IRB include the protection of human subjects
and the education of participants in the research. The ap-
proval process might be of interest to PIs. Revisions and
recommendations from the reviewers need the compli-
ance of the PIs. For the purpose of safety, [1] have out-
lined an accreditation process and a standardized system
for collecting and disseminating data on adverse events
and the performance assessment of IRBs. Appropriate ar-
rangements for prospective independent scientific and
ethical review are required, as are measures to establish
whether the IRB is satisfying federal regulations for re-
search studies that involve human research subjects [7].
Local IRBs like ours, the drug relative study was dir-
ectly measured as the observed variable for the latent
variable of vulnerability. The reason for patient safety is
that adverse drug events are monitored regularly [13].
Most common serious adverse events in a clinical setting
are related to drugs that are administered in our general
hospital. The risk level for consideration of institutional
responsibility about drug studies is higher than minimal
injury [12]. Indeed, in this study, we found the total re-
view time to be associated with the nature of the drug
study. As the path analysis indicated, the total review
time acted as a mediator between drug studies and ap-
proval. For genome studies, vulnerability was regarded
as a latent variable because of the large number of
Fig. 2 Maximal likelihood estimates of the following model parameters for regression weights, covariance and variance and the theoretical
framework on structural models between vulnerability, PIs, and review process on the approval outcome
Table 2 Estimates of observed and latent variables in the
measurement and structural model
Estimates S.E. C.R. P
PIs↔ Review −0.031 0.015 −2.054 0.040
Vulnerability ↔ Review 0.014 0.010 1.399 0.162
Vulnerability ↔ PIs −0.006 0.005 −1.273 0.203
Genome↔ Revision frequency 0.093 0.021 4.428 ***
Drug↔ Review time 1.515 0.616 2.460 0.014
Genome↔ Local PIs −0.047 0.013 −3.666 ***
Local PIs↔ Revision frequency −0.126 0.022 −5.645 ***
S.E. standard error, C.R. critical ratios
*** < 0.0001
Table 3 Model identification post modification and test by GFI,
AGFI, TLI, CFI, and RMSEA for model fitness
Model GFI AGFI TLI CFI RMSEA
Default model 0.975 0.937 0.933 0.967 0.044
Saturated model 1.000 1.000
Independence model 0.743 0.677 0.000 0.000 0.171
GFI goodness-of-fit index, AGFI adjusted goodness-of-fit index, TLI Tucker-Lewis
index, CFI comparative fit index, RMSEA root mean square error
of approximation
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genetic studies conducted worldwide in recent years,
even in developing countries. There are no consistent
standards in IRB review concerning new technology,
specimen storage, disclosure of individual research re-
sults, and ethical problems [16]. In the present study,
SEM found that PIs in our organization who were in-
volved in genetic studies submitted a larger number of
revised research proposals than people who did not con-
duct genetic research and who conducted genetic re-
search but were not affiliated with our organization. One
study found that, compared with IRB members, more
genetic researchers trusted the confidentiality of coded
data, fewer expected harm from re-identification, and
fewer considering re-consent necessary in certain sce-
narios [15]. Another report suggests that IRB members
might inflate the vulnerability of research subjects and
their inability to make decisions regarding the relative
risks and benefits of research [17]. Regardless of ethical,
scientific, or regulatory considerations, drug and genetic
studies pose particular challenges to the review process.
IRB members and reviewers need regular training about
issues common to multiple types of studies, as well as
those that are unique to certain fields.
With regard to PIs, those within our organization who
submitted requests for genetic studies were frequently
asked to revise their proposals. In this public hospital, re-
tired physicians follow the rule of official provision. The re-
tired age is 48 to 52 years old. The reason for this might be
that more junior PIs and less experienced research teams
were not familiar with the routine checklist for their pro-
posal [1] or that the regulations surrounding genetic stud-
ies were complex and thus delayed resubmission [10]. It
has been suggested that difficulties and delays with the
local IRB approval process sometimes result in investiga-
tors deciding to abandon research [9, 18]. The function of
any IRB is to not only protect human research subjects,
but also to educate researchers about the safe conduct of
research that involves human subjects [7]. We found the
latent variable of PIs moderated the other latent variable of
review, and thus affected approval. Many studies have fo-
cused on the review process and have demanded reform of
the IRB [1, 7]. Multiple revisions are often associated with
different interpretations; however, full review by an IRB is
recommended even for the initial review [7, 10]. Ineffi-
ciency is the most common complaint about the IRB [6, 7].
In our SEM, the total review time and revision frequency
played mediating roles in the review process. The latent
variables of vulnerability and PIs interacted with review
and acted as moderators of approval. Guidance of the PIs
and reviewers would improve the function of the IRB.
Limitations
There were several limitations to the present study. First,
we could not guarantee the use of consistent standards
amongst every scientific/non-scientific, affiliated/non-af-
filiated reviewer who reviewed the proposals. The
process or the review system provides reviews to the
same standard is a source of concern. Second, we did
not make reason analysis about the revision frequency
which could not clarify the role of PIs before reviewing
process. It needs advanced investigation. Third, the local
IRB data and conclusions reported here might not be
generalized to apply to other IRBs.
Conclusions
The revision frequency and total review time influenced
the review process, and the latent variable of reviewing
was the most important factor responsible for mediating
the PIs and vulnerability to IRB review approval. The local
PIs moderated with genetic study and revision frequency
affected the review process and mediated non-approval.
The drug study prolonged the total review time and medi-
ated non-approval. The review process is the mediator be-
tween vulnerability, PIs and approval. Guidance of the
investigators and reviewers involved in genetic and drug
studies would improve the function of the IRB.
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